Abstract Library

#4604 Germline predisposition to neuroendocrine tumours of the pancreas (pNEN) based on mutations in DNA repair genes – BRCA1, BRCA2, PALB2, CHEK2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, STK11

Introduction: Neuroendocrine tumours of the pancreas (pNEN) rank as the second most common epithelial neoplasms after pancreatic adenocarcinoma, with increasing prevalence and a mortality rate of 60%. Identifying germline mutations in DNA repair genes such as CHEK2, BRCA1/2, and MUTYH within pNEN cases may pave the way for personalised diagnostics and therapies.

Conference:

Presenting Author:

Authors: Jurecka Lubieniecka B, Ros-Mazurczyuk M, Oczko-Wojciechowska M, Cortez A, Handkiewicz-Junak D,

Keywords: pNEN, DNA repair genes,

#4585 Short-term observation of liver transplantation combined with multidisciplinary integrated treatment of liver metastases from neuroendocrine tumours beyond the Milan criteria

Introduction: The continuous progress of comprehensive treatment enables neuroendocrine tumour liver metastasis (NENLM) that meets Milan criteria to achieve longer survival without liver transplantation (LT). LT often faces high tumour burden, while comprehensive treatment also brings new opportunities for recurrence.

Conference:

Presenting Author: Chen C

Authors: Chen C, Jiang W, Chen J, Liang Y, Xie Y,

Keywords: liver transplantation, neuroendocrine tumour liver metastasis, Milan Criteria, comprehensive treatment,

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#4564 Vasculogenic mimicry in neuroendocrine tumour across different primary sites

Introduction: Anti-angiogenesis treatments targeting VEGFRs, including Surufatinib and Cabozantinib, etc. showed better efficacy for pancreatic neuroendocrine tumours (NET) than NET of other primary sites. Recent clinical trial targeting tumour necrosis factor receptor-associated protein-1, leading to inhibition of vasculogenic mimicry (VM) showed contrary results to current VEGFRs-targeted treatments. However, VM of NET across different primary sites are yet to be understood.

Conference:

Presenting Author: Chen L

Authors: Chen L, Liang Y, Huang D, Ji S, Chen J,

Keywords: neuroendocrine tumour, pancreatic, extra-pancreatic, vasculogenic mimicry,

#4560 Genetic trajectory and clonal evolution of non-functional pancreatic neuroendocrine tumours with lymph node and liver metastasis

Introduction: The systemic spread of panNETs is dominated by lymphatic reflux and portal system, exhibiting diverse patterns of metastasis without systematical genomic investigation.

Conference:

Presenting Author: Wu J

Authors: Wu J, Peng Y, Yin L, Jiang K, Li Q,

Keywords: Pan NET, Metastasis, Whole exome sequencing, Pylogenic tree,